Cancer Clinical Trials Information Platform in Hong Kong


  1. This serves merely as an information platform about cancer clinical trials operated by different institutions in Hong Kong. HKACS is not responsible for the contents, availability and operability of the trials listed.
  2. Respective institutions usually reserve all rights regarding the implementation and execution of their respective clinical trials.
  3. Patients usually need to satisfy a complex and stringent set of selection criteria before being selected/ included in certain clinical trials. Interested parties should contact respective institutions regarding further details of the trials


Cancer Site


*in alphabetical order (Last updated on 6/11/2020)


Stomach Cancer

Institution Study Title  
CUHK A phase 3,randomized, double-blind clinical study of pembrolizumab( mk-3475) pluschemotherapy versus placebo plus chemotherapy as first-line treatment inparticipants with her2 negative, previously untreated, unresectable ormetastatic gastric or gastroesophageal junction adenocarcinoma Click for Details
HKU A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as maintenance Therpy in Patiens with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy Click for Details
HKU A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus palcebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KEYNOTE-859) Click for Details


For Enquiry, please contact the respective institute, HKACS is not responsible for the outcomes of the clinical trials.